Vimy Pharmaceuticals raises $8.5M ahead of TSXV listing via reverse takeover
What's the deal? Vimy PharmaceuticalsDealroom has a profile for this one. Try Dealroom → has closed a brokered private placement of US$8.84M (roughly $8.5 million) and signed a definitive reverse-takeover agreement with Harmony Acquisitions Corp. (TSXV: MONY.P). The company issued 4,018,821 subscription receipts at US$2.2 each, with Beacon SecuritiesDealroom has a profile for this one. Try Dealroom → as lead agent.
What's the endgame? The combined entity plans to list on the TSX Venture Exchange under the ticker "VIMY." Vimy develops generic drugs, including semaglutide, and runs the VimyDirect online pharmacy platform.
Where's the money going? Net proceeds will fund research and development, faster international market entry, expanded Canadian manufacturing, and the VimyDirect platform. Vimy has filed Abbreviated New Drug Submissions to Health Canada for generic versions of Ozempic and Wegovy, both semaglutide injections.
Why now? Canadian semaglutide injection sales hit US$2.57B in 2025, up 31% year on year, the company said. That demand underpins Vimy's push to bring lower-cost generics to market.
How does the deal work? In a three-cornered amalgamation, Harmony will acquire all Vimy shares, followed by a 34-for-1 Vimy share split and a Harmony consolidation. About 31,520,296 shares will be outstanding afterwards, with existing Vimy shareholders holding roughly 86.19% and offering subscribers about 12.75%. Harmony will be renamed Vimy Pharmaceuticals Corp.
By the numbers. For the six months ending June 30, 2026, Vimy reported a net loss of US$942K and total assets of US$2.11M — figures that frame the placement as a meaningful capital boost for an early-stage business.
What could go wrong? The subscription receipts convert into shares only once escrow conditions are met; if they are not satisfied within 120 days of closing — extendable by 30 days — the receipts are cancelled and funds returned. The transaction is targeted to close by late October 2026, with a final deadline of November 30, 2026, and hinges on TSXV listing approval and a shareholder vote scheduled for October 19, 2026.
The signal: Vimy's raise and public-market debut reflect investor appetite for generic entrants chasing the fast-growing semaglutide market, where blockbuster weight-loss and diabetes drugs face looming competition from lower-cost alternatives.
Read more: kalkinemedia.com
Image credit: Generated with Gemini
